Searchable abstracts of presentations at key conferences in endocrinology

ea0046p8 | (1) | UKINETS2016

Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies

Modlin Irvin M , Frilling Andrea , Salem Ronald R , Alaimo Daniele , Drymousis Panagiotis , Wasan Harpreet S , Callahan Stephen , Faiz Omar , Weng Lei , Teixeira Nancy , Bodei Lisa , Drozdov Ignat , Kidd Mark

Background: Surgery is the only curative treatment for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), but the prediction of residual disease/recurrence is limited in the absence of optimal biomarkers. We examined whether a blood-based multianalyte neuroendocrine gene transcript assay (NETest) would define tumor cytoreduction and therapeutic efficacy.Methods: The NETest is a polymerase chain reaction–based analysis of 51 genes. Disease acti...

ea0072p1 | (1) | UKINETS2020

Post-operative NETest scores detect residual NET disease and accurately predicts tumor recurrence in R0

Modlin Irvin , Kidd Mark , Oberg Kjell , Falconi Massimo , Luigi Filosso5 Pier , Frilling Andrea , Malczewska Anna , Salem Ronald , Toumpanakis Christos , Laskaratos Faidon-Marios , Partelli Stefano , Roffinella Matteo , Arx Claudia von , Kos-Kudla Beata , Bodei Lisa , Drozdov Ignat , Kitz Alexandra

Introduction: Surgery is the only cure for neuroendocrine tumor (NET) disease. R0 resection is critical for successful tumor resection. Early detection of residual disease is key for optimal management. Both imaging and current biomarkers have intrinsic limitations and are largely ineffective up to 3 months post-surgery. NETest, a multigene blood biomarker test, identifies NETs with >90% accuracy. We hypothesized that surgery would decrease NETest levels and that elevated scor...